Landscapes / Companies
Furthest along
7 approved
3 in Phase 3
Drugs
17
in active trials · 65 in all
Trials
35 active
200 since 2021
Drugs17
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Amyloid-beta protofibril antibody |
Eisai |
Approved | 3 Dec 2026soonPhase 2 trial completes | ||
| Next date | 3 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Early Alzheimer's Disease, Preclinical Alzheimer's Disease and 2 more | ||||
| Open drug page | |||||
Interferon beta |
Approved | 20 May 2027Phase 3 trial completes | |||
| Next date | 20 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Multiple Sclerosis, Relapsing-Remitting | ||||
| Open drug page | |||||
Antisense oligonucleotide |
Approved | 26 May 2027Phase 4 trial completes | |||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | 26 May 2027 · Phase 4 trial completes | ||||
| Also tested for | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation, Amyotrophic Lateral Sclerosis | ||||
| Open drug page | |||||
Survival motor neuron-2-directed RNA Interaction; antisense oligonucleotide |
Approved | 24 Sep 2027Phase 3 trial completes | |||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | 24 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Spinal Muscular Atrophy, Muscular Atrophy, Spinal | ||||
| Open drug page | |||||
— |
Approved | 16 Nov 2027Phase 3 trial completes | |||
| Next date | 16 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Friedreich Ataxia | ||||
| Open drug page | |||||
— |
Approved | 28 Jul 2034Phase 3 trial completes | |||
| Next date | 28 Jul 2034 · Phase 3 trial completes | ||||
| Also tested for | Relapsing Forms of Multiple Sclerosis | ||||
| Open drug page | |||||
— |
Approved | 28 Jul 2034Phase 3 trial completes | |||
| Next date | 28 Jul 2034 · Phase 3 trial completes | ||||
| Also tested for | Relapsing Forms of Multiple Sclerosis | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 1 Dec 2026soonPhase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Antibody-mediated Rejection, Microvascular Inflammation and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | 23 Jun 2028Phase 3 trial completes | |||
| Next date | 23 Jun 2028 · Phase 3 trial completes | ||||
| Also tested for | Muscular Atrophy, Spinal, Spinal Muscular Atrophy | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 26 Jun 2029Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 26 Jun 2029 · Phase 3 trial completes | ||||
| Also tested for | Lupus Erythematosus, Systemic, Subacute Cutaneous Lupus Erythematosus and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 23 Jan 2034Phase 1/2 trial completes | |||
| Next date | 23 Jan 2034 · Phase 1/2 trial completes | ||||
| Also tested for | Amyotrophic Lateral Sclerosis | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia | ||||
| Open drug page | |||||
— |
Phase 1 | 2 Feb 2027Phase 1 trial completes | |||
| Next date | 2 Feb 2027 · Phase 1 trial completes | ||||
| Open drug page | |||||
— |
Phase 1 | 7 Apr 2027Phase 1 trial completes | |||
| Next date | 7 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Neutropenia (Low White Blood Cell Count) | ||||
| Open drug page | |||||
— |
Phase 1 | 19 Jun 2028Phase 1 trial completes | |||
| Next date | 19 Jun 2028 · Phase 1 trial completes | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Open drug page | |||||
No drugs match “”.
SEC filings
All on SEC.govNo filings loaded yet.
About
- No active trial
- 48 other drugs
- Registry names
- 9 names in ClinicalTrials.gov Biogen
HI-Bio, A Biogen Company
Vascular Biogenics Ltd. operating as VBL Therapeutics
NeuroBiogen Co., Ltd
Reata, a wholly owned subsidiary of Biogen
Carbiogene Therapeutics Co. Ltd.
BioGeneric Pharma
BioGene Pharmaceutical Ltd.
BioGenCell Ltd. - Sources
- ClinicalTrials.gov updated 18 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021